Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

January 20, 2022

Study Completion Date

January 20, 2022

Conditions

Chronic Migraine

Interventions

DRUG

Atogepant

Oral Tablet

Trial Locations (3)

Chinese PLA General Hospital /ID# 227546, Beijing

The second Affiliated hospital of Zhejiang University school of Medicine /ID# 227558, Hangzhou

The Second Hospital of Shanxi Medical University /ID# 227567, Taiyuan